Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
|Articles|May 9, 2022
Daily Medication Pearl: Mitomycin (Jelmyto)
Author(s)Saro Arakelians, PharmD
Jelmyto is an alkylating drug indicated for the treatment of adult patients with low-grade upper tract urothelial cancer.
Advertisement
Medication Pearl of the Day: Mitomycin (Jelmyto)
Indication: Jelmyto is an alkylating drug indicated for the treatment of adult patients with low-grade upper tract urothelial cancer.
Insight:
- Dosing: Administer 1.3 g of sodium bicarbonate orally the evening prior to, the morning of, and 30 minutes prior to instillation procedure.
- Dosage forms: Two 40 mg (each) single-dose vials of mitomycin for pyelocalyceal solution.
- Adverse events: The most common adverse reactions (≥ 20%) are ureteric obstruction, flank pain, urinary tract infection, hematuria, renal dysfunction, fatigue, nausea, abdominal pain, dysuria, and vomiting.
- Mechanism of action: Mitomycin inhibits the synthesis of DNA. The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.
- Manufacturer: UroGen Pharma
Source:
Advertisement
Related to this article
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.
The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
A randomized clinical trial found that dedicated oncology pharmacist care reduced adverse drug reactions among patients with hematologic malignancies.
ENDURANCE trial finds fixed 2-year lenalidomide maintenance matches continuous therapy for standard-risk multiple myeloma survival, guiding oncology pharmacists on MM regimen toxicity.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
3
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
4
Flu Vaccination Linked to Fewer Severe Outcomes in Older Adults, Fewer ED Visits in Children
5